Anti-eIF2B3 antibody - Carboxyterminal end (ab71248)

Overview

  • Product name
    Anti-eIF2B3 antibody - Carboxyterminal end
    See all eIF2B3 primary antibodies
  • Description
    Rabbit polyclonal to eIF2B3 - Carboxyterminal end
  • Tested applications
    Suitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human eIF2B3 (C terminal) conjugated to Keyhole Limpet Haemocyanin (KLH).

  • Positive control
    • A375 cell line lysate.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    Preservative: 0.09% Sodium Azide
    Constituents: PBS
  • Concentration information loading...
  • Purity
    Ammonium Sulphate Precipitation
  • Purification notes
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab71248 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Detects a band of approximately 27 kDa (predicted molecular weight: 32 kDa).
ELISA 1/1000.

Target

  • Function
    Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP.
  • Involvement in disease
    Defects in EIF2B3 are a cause of leukodystrophy with vanishing white matter (VWM) [MIM:603896]. VWM is a leukodystrophy that occurs mainly in children. Neurological signs include progressive cerebellar ataxia, spasticity, inconstant optic atrophy and relatively preserved mental abilities. The disease is chronic-progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. While childhood onset is the most common form of the disorder, some severe forms are apparent at birth. A severe, early-onset form seen among the Cree and Chippewayan populations of Quebec and Manitoba is called Cree leukoencephalopathy. Milder forms may not become evident until adolescence or adulthood. Some females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.
  • Sequence similarities
    Belongs to the eIF-2B gamma/epsilon subunits family.
  • Information by UniProt
  • Database links
  • Form
    It localizes to the cytosol.
  • Alternative names
    • EI2BG_HUMAN antibody
    • EIF 2B antibody
    • eIF 2B GDP GTP exchange factor subunit gamma antibody
    • eIF-2B GDP-GTP exchange factor subunit gamma antibody
    • eIF2B-gamma antibody
    • Eif2b3 antibody
    • EIF2Bgamma antibody
    • Eukaryotic translation initiation factor 2B subunit 3 gamma antibody
    • Eukaryotic translation initiation factor 2B, gamma antibody
    • eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa antibody
    • OTTHUMP00000010262 antibody
    • OTTHUMP00000010263 antibody
    • Translation initiation factor eIF-2B subunit gamma antibody
    see all

Anti-eIF2B3 antibody - Carboxyterminal end images

  • Anti-eIF2B3 antibody - Carboxyterminal end (ab71248) at 1/100 dilution + A375 cell line lysate at 12.5 µg

    Predicted band size : 32 kDa
    Observed band size : 27 kDa (why is the actual band size different from the predicted?)

References for Anti-eIF2B3 antibody - Carboxyterminal end (ab71248)

ab71248 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab71248.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up